Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)

637 Background: ddAC-paclitaxel (P) is superior to q3w AC-P. Both are associated w/ a 50%). Pts w/ unstable angina, CHF, or recent MI were excluded. MUGA was repeated after completion of ddACx4. Subsequent therapy (Rx) was determined per protocol guidelines of LVEF. Results: From Jan ‘05 to Dec ‘07, 185 pts were enrolled in 3 trials. Median age was 49yrs (range 27...